Cargando…
Effects of alfacalcidol on cardiovascular outcomes according to alkaline phosphatase levels in the J-DAVID trial
In the Japan Dialysis Active Vitamin D (J-DAVID) trial, oral alfacalcidol numerically, but not significantly, increased the risk of cardiovascular events among patients undergoing hemodialysis. Because the cardiovascular effect of alfacalcidol could be modulated by bone turnover status, this post-ho...
Autores principales: | Oka, Tatsufumi, Sakaguchi, Yusuke, Isaka, Yoshitaka, Ishii, Haruka, Kabata, Daijiro, Shintani, Ayumi, Nakatani, Shinya, Morioka, Tomoaki, Mori, Katsuhito, Inaba, Masaaki, Emoto, Masanori, Shoji, Tetsuo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9475027/ https://www.ncbi.nlm.nih.gov/pubmed/36104443 http://dx.doi.org/10.1038/s41598-022-19820-2 |
Ejemplares similares
-
Dialysate calcium, alfacalcidol, and clinical outcomes: A post-hoc analysis of the J-DAVID trial
por: Iseki, Kunitoshi, et al.
Publicado: (2022) -
Associations of time-dependent changes in phosphorus levels with cardiovascular diseases in patients undergoing hemodialysis: results from the Japan Dialysis Active Vitamin D (J-DAVID) randomized clinical trial
por: Koshi-Ito, Eri, et al.
Publicado: (2022) -
Oxidative Stress and Inflammation as Predictors of Mortality and Cardiovascular Events in Hemodialysis Patients: The DREAM Cohort
por: Sasaki, Keyaki, et al.
Publicado: (2021) -
Plasma homocysteine and cerebral small vessel disease as possible mediators between kidney and cognitive functions in patients with diabetes mellitus
por: Sonoda, Mika, et al.
Publicado: (2017) -
Cinacalcet may suppress kidney enlargement in hemodialysis patients with autosomal dominant polycystic kidney disease
por: Nakatani, Shinya, et al.
Publicado: (2021)